Snapshot from Jul 29, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Erasca class action securities lawsuit
Regulatory securities class action

Erasca class action securities lawsuit

Analysis based on 6 articles · First reported Jul 21, 2026 · Last updated Jul 29, 2026

Sentiment
-30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The lawsuit may negatively impact Erasca's stock price due to allegations of securities fraud and potential liability. Investor confidence could be shaken, leading to increased volatility and possible settlement costs.

Biotechnology Pharmaceuticals
Event Summary

Kahn Swick & Foti, LLC (KSF) and partner Charles Foti filed a class action securities lawsuit against Erasca on behalf of investors who purchased Erasca shares between January 14, 2025 and April 26, 2026. The lawsuit, pending in the United States — United States District Court for the Southern District of California, alleges that Erasca and certain executives failed to disclose material information, including that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc., placing Erasca at risk of violating patent and trade secret protections. Investors have until August 10, 2026 to seek lead plaintiff status.

Key Actions
100 Erasca made false statements
80 Kahn Swick & Foti notifies investors of lawsuit Erasca
Entities Involved
stock
Erasca
Erasca is the defendant in the class action lawsuit, facing allegations of securities fraud related to its ERAS-0015 product. The company's reputation and stock price may suffer.
Importance 100.0 Sentiment -40.0
priv
Kahn Swick & Foti
KSF is the law firm representing the plaintiff class, seeking recoveries for investors. The firm gains visibility from this high-profile case.
Importance 60.0 Sentiment 10.0
stock
Revolution Medicines
Revolution Medicines is referenced in the complaint as the company to which Erasca allegedly made improper comparisons, potentially highlighting competitive dynamics.
Importance 40.0 Sentiment 10.0
per
Charles Foti
Charles Foti, former Louisiana Attorney General and KSF partner, is involved in the lawsuit as a named partner, lending credibility to the case.
Importance 30.0 Sentiment 5.0
per
Lewis Kahn
Lewis Kahn is the managing partner at KSF and the primary contact for investors, playing a key role in the litigation.
Importance 20.0 Sentiment 5.0
govactor
United States — United States District Court for the Southern District of California
The court is where the lawsuit is pending, serving as the judicial venue for the case.
Importance 10.0 Sentiment 0.0
Relationships
Erasca related ↔ Kahn Swick & Foti
Erasca competitor ↔ Revolution Medicines Erasca is a clinical-stage oncology company that directly competes with Revolution Medicines in developing pan-RAS molec
Kahn Swick & Foti related ↔ Revolution Medicines
Kahn Swick & Foti related ↔ Charles Foti
Kahn Swick & Foti related ↔ Lewis Kahn
Charles Foti partner ↔ Lewis Kahn Charles Foti is a partner at Kahn Swick & Foti, LLC, a prominent securities litigation law firm where Lewis Kahn serves
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.